<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00987324</url>
  </required_header>
  <id_info>
    <org_study_id>GE IDE NO. S02908</org_study_id>
    <nct_id>NCT00987324</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Paclitaxel-eluting Balloon, -Stent vs. Plain Angioplasty for Drug-eluting Stent Restenosis</brief_title>
  <acronym>ISAR-DESIRE-3</acronym>
  <official_title>Randomized Trial of Paclitaxel-Eluting Balloon, Paclitaxel-Eluting Stent and Plain Balloon Angioplasty for Restenosis in &quot;-Limus&quot;-Eluting Coronary Stents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this randomized study is to determine which treatment option, either
      paclitaxel-eluting balloon, paclitaxel-eluting stent or plain balloon angioplasty is the most
      effective in the treatment of restenosis after implantation of &quot;Limus&quot;-eluting stents, (LES).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The use of drug-eluting stents (DES) has led to a drastic reduction of restenosis rates
      compared to bare metal stents (BMS), but 5% to 10% of patients receiving DES are still in
      need of revascularization of the treated vessel. Two important families of drugs are used for
      stent coating: paclitaxel belonging to the taxane family, and the &quot;limus&quot;-family such as
      sirolimus, everolimus, zotarolimus, biolimus A9 and pimecrolimus.

      Data regarding the optimal treatment of in-DES-restenosis is very limited. Implanting a new
      DES for in-DES-restenosis has been reported to be associated with re-restenosis rates as high
      as 43%. Several recent well published studies have shown a substantial reduction of
      restenosis using paclitaxel-eluting balloons (PEB) for de-novo lesions and BMS-restenotic
      lesions.

      The objective of this randomized trial is to assess the hypothesis, that PEB are non-inferior
      to paclitaxel-eluting-stents (PES) for restenosis in &quot;limus&quot;-eluting-stents (LES), and both,
      PEB and PES, are superior to plain angioplasty in patients with restenosis after initial LES
      implantation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent in-segment diameter stenosis at follow-up angiography</measure>
    <time_frame>6-8 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>In-segment minimal luminal diameter</measure>
    <time_frame>6-8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-segment binary angiographic restenosis</measure>
    <time_frame>6-8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined incidence of death or myocardial infarction</measure>
    <time_frame>1 and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of thrombosis</measure>
    <time_frame>1 and 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">402</enrollment>
  <condition>Heart Disease</condition>
  <condition>Ischemia</condition>
  <condition>Restenosis</condition>
  <arm_group>
    <arm_group_label>Paclitaxel-eluting stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel-eluting stent (Taxus)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Plain Balloon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>plain balloon angioplasty</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paclitaxel-eluting balloon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SeQuent Please</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Taxus stent</intervention_name>
    <description>Implantation of paclitaxel-eluting stent</description>
    <arm_group_label>Paclitaxel-eluting stent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SeQuent Please</intervention_name>
    <description>Dilation with SeQuent Please (paclitaxel-eluting balloon)</description>
    <arm_group_label>Paclitaxel-eluting balloon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Conventional Balloon Catheter</intervention_name>
    <description>Ryuijin, Trek</description>
    <arm_group_label>Plain Balloon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with ischemic symptoms or evidence of myocardial ischemia in the presence of
             ≥ 50% restenosis after prior implantation of LES in native coronary vessels.

          2. Written, informed consent by the patient or her/his legally-authorized representative
             for participation in the study.

          3. In women with childbearing potential a negative pregnancy test is mandatory.

        Exclusion Criteria:

          1. Age &lt; 18 years.

          2. Cardiogenic shock.

          3. Acute ST-elevation myocardial infarction within 48 hours from symptom onset.

          4. Target lesion located in the left main trunk or bypass graft.

          5. Target lesion located in small vessel (vessel size &lt; 2.0 mm).

          6. Malignancies or other comorbid conditions (for example severe liver, renal and
             pancreatic disease) with life expectancy less than 12 months or that may result in
             protocol non-compliance.

          7. Severe renal insufficiency (glomerular filtration rate ≤ 30 ml/min).

          8. Contraindications to antiplatelet therapy, paclitaxel, stainless steel, cobalt,
             chrome.

          9. Pregnancy (present, suspected or planned) or positive pregnancy test.

         10. Previous enrollment in this trial.

         11. Patient's inability to fully comply with the study protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julinda Mehilli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsches Herzzentrum Munich</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adnan Kastrati, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Deutsches Herzzentrum</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Klaus Tiroch, MD</last_name>
    <role>Study Director</role>
    <affiliation>Deutsches Herzzentrum</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1. Med. Klinik, Klinikum rechts der Isar</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz-Zentrum</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum</name>
      <address>
        <city>Munich</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Unverdorben M, Vallbracht C, Cremers B, Heuer H, Hengstenberg C, Maikowski C, Werner GS, Antoni D, Kleber FX, Bocksch W, Leschke M, Ackermann H, Boxberger M, Speck U, Degenhardt R, Scheller B. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation. 2009 Jun 16;119(23):2986-94. doi: 10.1161/CIRCULATIONAHA.108.839282. Epub 2009 Jun 1.</citation>
    <PMID>19487593</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2009</study_first_submitted>
  <study_first_submitted_qc>September 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2009</study_first_posted>
  <last_update_submitted>November 18, 2016</last_update_submitted>
  <last_update_submitted_qc>November 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

